These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


79 related items for PubMed ID: 21567034

  • 1. Resistance to 1-Beta-d-arabinofuranosylcytosine and hypersensitivity to bleomycin in ataxia-telangiectasia B-lymphoblastoid cell-lines.
    Li M, Shiraishi Y.
    Int J Oncol; 1994 Jun; 4(6):1173-81. PubMed ID: 21567034
    [Abstract] [Full Text] [Related]

  • 2. Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
    Grant S, Bhalla K, McCrady C.
    Leuk Res; 1991 Jun; 15(4):205-13. PubMed ID: 2030601
    [Abstract] [Full Text] [Related]

  • 3. Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine.
    Riccardi R, Chabner B, Glaubiger DL, Wood J, Poplack DG.
    Cancer Res; 1982 May; 42(5):1736-9. PubMed ID: 6896013
    [Abstract] [Full Text] [Related]

  • 4. Effect of tetrahydrouridine on the action of 1-beta-D-arabinofuranosylcytosine in synchronized cultures of normal rat kidney cells.
    Wan CW, Mak TW.
    Cancer Res; 1979 Oct; 39(10):3981-5. PubMed ID: 476637
    [Abstract] [Full Text] [Related]

  • 5. Effect of tetrahydrouridine on metabolism and transport of 1-beta-D-arabinofuranosylcytosine in human cells.
    Riva C, Barra Y, Carcassonne Y, Cano JP, Rustum Y.
    Chemotherapy; 1992 Oct; 38(5):358-66. PubMed ID: 1286578
    [Abstract] [Full Text] [Related]

  • 6. Modulation of the effect of 1-beta-D-arabinofuranosylcytosine based on changes of cytidine deaminase activity in HL60 cells.
    Mejer JN, Mortensen BT, Christensen IJ.
    Med Oncol Tumor Pharmacother; 1990 Oct; 7(1):25-9. PubMed ID: 2338846
    [Abstract] [Full Text] [Related]

  • 7. Isolation and characterization of a 1-beta-D-arabinofuranosylcytosine-resistant Chinese hamster ovary cell mutant that is also X-ray sensitive and is noncomplementary with ataxia telangiectasia cells.
    Preston GA, Payne HS, Preston RJ.
    Cancer Res; 1992 Jan 15; 52(2):319-27. PubMed ID: 1728406
    [Abstract] [Full Text] [Related]

  • 8. Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours.
    Kreis W, Chan K, Budman DR, Schulman P, Allen S, Weiselberg L, Lichtman S, Henderson V, Freeman J, Deere M.
    Cancer Res; 1988 Mar 01; 48(5):1337-42. PubMed ID: 3342412
    [Abstract] [Full Text] [Related]

  • 9. Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.
    Kreis W, Hession C, Soricelli A, Scully K.
    Cancer Treat Rep; 1977 Oct 01; 61(7):1355-64. PubMed ID: 589601
    [Abstract] [Full Text] [Related]

  • 10. Cytogenetic response of normal human and ataxia telangiectasia G2 cells exposed to X-rays and ara C.
    Mozdarani H, Bryant PE.
    Mutat Res; 1989 Aug 01; 226(4):223-8. PubMed ID: 2761563
    [Abstract] [Full Text] [Related]

  • 11. Substrate-specific deoxycytidine kinase deficiency in 1-beta-D-arabinofuranosylcytosine-resistant leukemic cells.
    Richel DJ, Colly LP, Arkesteijn GJ, Arentsen-Honders MW, Kerster MG, ter Riet PM, Willemze R.
    Cancer Res; 1990 Oct 15; 50(20):6515-9. PubMed ID: 2208110
    [Abstract] [Full Text] [Related]

  • 12. Heterogeneity in chromosome damage and repair rates after bleomycin in ataxia telangiectasia cells.
    Hittelman WN, Sen P.
    Cancer Res; 1988 Jan 15; 48(2):276-9. PubMed ID: 2446745
    [Abstract] [Full Text] [Related]

  • 13. Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-beta-D-arabinofuranosylcytosine.
    Grant S, Turner A, Nelms P, Yanovich S.
    Leukemia; 1995 May 15; 9(5):808-14. PubMed ID: 7769843
    [Abstract] [Full Text] [Related]

  • 14. Suppressive effect of novobiocin on the frequency of chromosome-type aberrations induced by ara C in the G1 phase of human lymphocytes.
    Kishi K.
    Mutat Res; 1988 Jun 15; 208(2):109-13. PubMed ID: 3132613
    [Abstract] [Full Text] [Related]

  • 15. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.
    Kreis W, Budman DR, Chan K, Allen SL, Schulman P, Lichtman S, Weiselberg L, Schuster M, Freeman J, Akerman S.
    Leukemia; 1991 Nov 15; 5(11):991-8. PubMed ID: 1961042
    [Abstract] [Full Text] [Related]

  • 16. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
    Avramis VI, Powell W.
    Cancer Invest; 1987 Nov 15; 5(4):293-9. PubMed ID: 3664332
    [Abstract] [Full Text] [Related]

  • 17. Enhancement of frequencies of restriction endonuclease-induced chromatid breaks by arabinoside adenine in normal human and ataxia telangiectasia cells.
    Liu N, Bryant PE.
    Int J Radiat Biol; 1997 Sep 15; 72(3):285-92. PubMed ID: 9298108
    [Abstract] [Full Text] [Related]

  • 18. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines.
    Kees UR, Ford J, Dawson VM, Piall E, Aherne GW.
    Cancer Res; 1989 Jun 01; 49(11):3015-9. PubMed ID: 2720661
    [Abstract] [Full Text] [Related]

  • 19. Enhanced expression of X-ray- and UV-induced chromosome aberrations by cytosine arabinoside in ataxia telangiectasia cells.
    Ejima Y, Sasaki MS.
    Mutat Res; 1986 Jun 01; 159(1-2):117-23. PubMed ID: 3941661
    [Abstract] [Full Text] [Related]

  • 20. Induction of resistance to 1-beta-D-arabinofuranosylcytosine in human H9 cell line by simian immunodeficiency virus.
    Yusa K, Oh-hara T, Tsuruo T.
    Biochem Biophys Res Commun; 1995 Jan 17; 206(2):486-91. PubMed ID: 7826366
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 4.